Compare FWRD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | CGEM |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 1.4B |
| IPO Year | 2024 | 2020 |
| Metric | FWRD | CGEM |
|---|---|---|
| Price | $16.69 | $20.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $37.50 | $30.13 |
| AVG Volume (30 Days) | 410.5K | ★ 701.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.86 | $5.68 |
| 52 Week High | $31.18 | $23.19 |
| Indicator | FWRD | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 43.84 |
| Support Level | $15.87 | $11.87 |
| Resistance Level | $16.77 | $23.19 |
| Average True Range (ATR) | 0.76 | 0.92 |
| MACD | -0.23 | -0.38 |
| Stochastic Oscillator | 11.67 | 30.77 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.